Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

20190513 PR IND TG4050 EN

Published 13 May 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

20190509 PR financial meetings Q2 19

Published 9 May 2019
Categorized as 2019, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019

20190509MISE A DISPO AG – US

Published 9 May 2019
Categorized as 2019, Press release

Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies

20190502 – TG-AZ agreement – ENG

Published 2 May 2019
Categorized as 2019, Invir.IO, Press release

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane. M. Harper, et al. Gynecologic Oncology, April 2019 – Download the article The publication has been featured in The Lancet Oncology and Medpage Today Publication

Published 18 April 2019
Categorized as -others, 2018, 2019, Publication, TG4001, TG6002 (FR)

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster

Published 18 April 2019
Categorized as -others, 2019, Publication, publication key en, TG4001, TG4001

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 – Download the article Publication

Published 27 March 2019
Categorized as -others, 2019, Publication, TG6002

Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

20190326 PR BioInvent extension CDR US

Published 26 March 2019
Categorized as 2019, Invir.IO, Press release

Transgene: A positive 2018, moving ahead with a strong portfolio

20180320 FY RESULTS EN

Published 20 March 2019
Categorized as 2019, Press release

Transgene secures a €20 Million Revolving Credit Facility with Natixis

20190318 PR Natixis loan EN

Published 18 March 2019
Categorized as 2019, Press release

Posts pagination

Newer posts Page 1 … Page 30 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu